Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: Insight into EGFR and ERK1/2 as antitumor targets

Biochemical Pharmacology

Volumn 82, Issue 10, 2011, Pages 1467-1477

  Barbieri, Federica ^a   Würth, Roberto ^a   Favoni, Roberto E ^b   Pattarozzi, Alessandra ^a   Gatti, Monica ^a   Ratto, Alessandra ^c   Ferrari, Angelo ^c   Bajetto, Adriana ^a   Florio, Tullio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c LIGURIA E VALLE D AOSTA   (Italy)

Author keywords

EGFR; Mesothelioma; Proliferation; Tyrosine kinase inhibitors

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; VASCULOTROPIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB;

APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; DIMERIZATION; HUMAN; HUMAN CELL; IC 50; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; BINDING ASSAY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MESOTHELIOMA; PLEURAL NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80054701704     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.073     Document Type: Conference Paper

References (44)

1. H. Yang, J.R. Testa, and M. Carbone Mesothelioma epidemiology, carcinogenesis, and pathogenesis Current Treatment Options in Oncology 9 2008 147 157
2. J.P. Steele, and A. Klabatsa Chemotherapy options and new advances in malignant pleural mesothelioma Annals of Oncology 16 2005 345 351 (Pubitemid 40458309)
3. R.E. Favoni, and T. Florio Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma Trends in Pharmacological Sciences 2011 10.1016/j.tips.2011.03.011
4. M. Ray, and H.L. Kindler Malignant pleural mesothelioma: an update on biomarkers and treatment Chest 136 2009 888 896
5. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma Journal of Clinical Oncology 21 2003 2636 2644 (Pubitemid 46606305)
6. J. Stebbing, T. Powles, K. McPherson, J. Shamash, P. Wells, and M.T. Sheaff The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma Lung Cancer 63 2009 94 97
7. P. Bertino, C. Porta, D. Barbone, S. Germano, S. Busacca, and S. Pinato Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed Thorax 62 2007 690 695 (Pubitemid 47235011)
8. P. Bertino, F. Piccardi, C. Porta, R. Favoni, M. Cilli, and L. Mutti Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts Clinical Cancer Research 14 2008 541 548 (Pubitemid 351226124)
9. P.A. Zucali, G.L. Ceresoli, F. De Vincenzo, M. Simonelli, E. Lorenzi, and L. Gianoncelli Advances in the biology of malignant pleural mesothelioma Cancer Treatment Reviews 2011 10.1016/j.ctrv.2011.01.001
10. A.W. Langerak, van der, C.A. Linden-van Beurden, and M.A. Versnel Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines Biochimica et Biophysica Acta 1305 1996 63 70 (Pubitemid 26051947)
11. H. Dazzi, P.S. Hasleton, N. Thatcher, S. Wilkes, R. Swindell, and A.K. Chatterjee Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R) relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody British Journal of Cancer 61 1990 924 926 (Pubitemid 20197007)
12. A. Destro, G.L. Ceresoli, M. Falleni, P.A. Zucali, E. Morenghi, and P. Bianchi EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations Lung Cancer 51 2006 207 215 (Pubitemid 43144364)
13. J.G. Edwards, D.E. Swinson, J.L. Jones, D.A. Waller, and K.J. O'Byrne EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma Lung Cancer 54 2006 399 407 (Pubitemid 44634142)
14. J.C. Pache, Y.M. Janssen, E.S. Walsh, T.R. Quinlan, C.L. Zanella, and R.B. Low Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers American Journal of Pathology 152 1998 333 340 (Pubitemid 28106377)
15. O. Rena, L.R. Boldorini, E. Gaudino, and C. Casadio Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations Journal of Surgical Oncology 2011 10.1002/jso.21901
16. E. Giovannetti, L. Erdem, E. Olcay, L.G. Leon, and G.J. Peters Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer Frontiers in Bioscience 16 2011 116 130
17. P.A. Janne, M.L. Taffaro, R. Salgia, and B.E. Johnson Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma Cancer Research 62 2002 5242 5247 (Pubitemid 35024597)
18. R.E. Favoni, A. Pattarozzi, M. Lo Casto, F. Barbieri, M. Gatti, and L. Paleari Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation Current Cancer Drug Targets 10 2010 176 191
19. Y. She, F. Lee, J. Chen, A. Haimovitz-Friedman, V.A. Miller, and V.R. Rusch The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index Clinical Cancer Research 9 2003 3773 3778 (Pubitemid 37169247)
20. R. Govindan, R.A. Kratzke, J.E. Herndon 2nd, G.A. Niehans, R. Vollmer, and D. Watson Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Clinical Cancer Research 11 2005 2300 2304 (Pubitemid 40490190)
21. L.L. Garland, C. Rankin, D.R. Gandara, S.E. Rivkin, K.M. Scott, and R.B. Nagle Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study Journal of Clinical Oncology 25 2007 2406 2413 (Pubitemid 46999211)
22. A.M. Orengo, L. Spoletini, A. Procopio, R.E. Favoni, A. De Cupis, and A. Ardizzoni Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis European Respiratory Journal 13 1999 527 534 (Pubitemid 29180160)
23. F. Griffero, A. Daga, D. Marubbi, M.C. Capra, A. Melotti, and A. Pattarozzi Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors The Journal of Biological Chemistry 284 2009 7138 7148
24. R. Iuliano, C. Raso, A. Quintiero, I.L. Pera, F. Pichiorri, and T. Palumbo The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization Journal of Biochemistry 145 2009 377 385
25. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacological Reviews 58 2006 621 681
26. A. Pattarozzi, M. Gatti, F. Barbieri, R. Wurth, C. Porcile, and G. Lunardi 17 beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment Molecular Pharmacology 73 2008 191 202 (Pubitemid 350294210)
27. C. Porcile, A. Bajetto, F. Barbieri, S. Barbero, R. Bonavia, and M. Biglieri Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation Experimental Cell Research 308 2005 241 253
28. T. Florio, A. Scorziello, M. Fattore, V. D'Alto, S. Salzano, and G. Rossi Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity impairment of the somatostatinergic effects by stable expression of E1A viral oncogene The Journal of Biological Chemistry 271 1996 6129 6136
29. A. de Cupis, C. Semino, P. Pirani, M. Loprevite, A. Ardizzoni, and R.E. Favoni Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines European Journal of Pharmacology 473 2003 83 95 (Pubitemid 36929872)
30. H.L. Kindler Systemic treatments for mesothelioma: standard and novel Current Treatment Options in Oncology 9 2008 171 179
31. S.K. Pal, R.A. Figlin, and K. Reckamp Targeted therapies for non-small cell lung cancer: an evolving landscape Molecular Cancer Therapeutics 9 2010 1931 1944
32. J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, and J. Arribas ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clinical Cancer Research 9 2003 1274 1283 (Pubitemid 36418377)
33. C.L. Arteaga, T.T. Ramsey, L.K. Shawver, and C.A. Guyer Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site The Journal of Biological Chemistry 272 1997 23247 23254 (Pubitemid 27392460)
34. A.H. Clayton, F. Walker, S.G. Orchard, C. Henderson, D. Fuchs, and J. Rothacker Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis The Journal of Biological Chemistry 280 2005 30392 30399 (Pubitemid 41216222)
35. S.P. Faux, C.E. Houghton, A. Hubbard, and G. Patrick Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres Carcinogenesis 21 2000 2275 2280 (Pubitemid 32049235)
36. L. Strizzi, A. Catalano, G. Vianale, S. Orecchia, A. Casalini, and G. Tassi Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma The Journal of Pathology 193 2001 468 475 (Pubitemid 32266815)
37. M. Bagia, and A.K. Nowak Novel Targeted Therapies and Vaccination Strategies for Mesothelioma Current Treatment Options in Oncology 2011 10.1001/7s11864-011-0149-1
38. S.R. Kalmadi, C. Rankin, M.J. Kraut, A.D. Jacobs, D.P. Petrylak, and D.J. Adelstein Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810) Lung Cancer 60 2008 259 263 (Pubitemid 351609140)
39. J.E. Nutt, K. O'Toole, D. Gonzalez, and J. Lunec Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines European Journal of Cancer 45 2009 1684 1691
40. V. Agarwal, M.J. Lind, and L. Cawkwell Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand? Cancer Treat Rev 2011 10.1016/j.ctrv.2010.11.004
41. P.A. Rascoe, X. Cao, J.C. Daniel, S.D. Miller, and W.R. Smythe Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma Journal of Thoracic and Cardiovascular Surgery 130 2005 393 400 (Pubitemid 41074170)
42. D. Stoppoloni, C. Canino, I. Cardillo, A. Verdina, A. Baldi, and A. Sacchi Synergistic effect of gefitinib and rofecoxib in mesothelioma cells Molecular Cancer 9 2010 27 36
43. I. Mohiuddin, X. Cao, M.K. Ozvaran, L. Zumstein, S. Chada, and W.R. Smithe Phosphatase tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of Akt phosphorylation Annals of Surgical Oncology 9 2002 310 316 (Pubitemid 34298638)
44. M.L. Janmaar, F.A. Kruyt, J.A. Rodriguez, and G. Giaccone Response to epidermal growth factor receptor inhibitors in non-small lung cancer cells. Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clinical Cancer Research 9 2003 2316 2326 (Pubitemid 36687658)